TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc.
(Nasdaq: AXDX ) today announced financial results for the second quarter ended June 30, 2024 . "During the quarter we completed our pre-clinical trial demonstrating strong analytical performance of our WAVE TM System and Gram-Negative Positive Blood Culture (PBC) assay. We are pleased to announce our pre-clinical trial was a success," commented Jack Phillips , President and CEO of Accelerate Diagnostics, Inc.
"Additionally, we were able to raise an additional $15 million with certain existing noteholders, which we anticipate will fund the company through 2025 and provide us runway to further deliver on our Wave strategic milestones," Mr. Phillips continued. Second Quarter 2024 Operating Highlights Notable WAVE program achievements during the quarter included: Conducted a successful pre-clinical trial for our WAVE system and Gram Positive PBC assay with strong analytical performance.
1,570 WAVE results compared to Broth Microdilution ( BMD ), with overall Essential and Categorical Agreements of approximately 95% and demonstrated strong reliability. Demonstrated system ease-of-use and minimal hands-on-time preanalytical PBC workflow with clinical microbiologists. Executed contract extensions with several strategic customers securing approximately 75% of U.
S . Pheno ® customer base to longer-term contracts ahead of the WAVE commercial launch. In the United States , added five new contracted Pheno instrume.